Cyclo3pss Corporation (CYPS) Aktienanalyse
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Mit einem Kurs von $ ist Cyclo3pss Corporation (CYPS) ein Healthcare-Unternehmen mit einer Bewertung von 0. Die Aktie erzielt 53/100, eine moderate Bewertung basierend auf 9 quantitativen KPIs.
Zuletzt analysiert: 15. März 2026Cyclo3pss Corporation (CYPS) Gesundheitswesen & Pipeline-Uebersicht
Cyclo3pss Corporation, an OTC-listed entity in the healthcare sector, specializes in ozone technology for food processing and laundry systems. Despite suspending operations in 2002 due to financial constraints, the company maintains its focus on sterilization and disinfection technologies, operating with a negative profit margin and high beta.
Investmentthese
Cyclo3pss Corporation presents a speculative investment opportunity due to its current operational suspension and OTC listing. The company's historical focus on ozone technology for food processing and laundry systems could represent potential value if operations were to resume. However, the negative profit margin of -232.3% and negative free cash flow indicate severe financial distress. The extremely high beta of 41.00 suggests very high volatility relative to the market. Any investment would depend on the potential for a turnaround, new financing, or strategic acquisition, all of which are highly uncertain. Investors should carefully consider the risks associated with OTC-listed companies and the lack of current operations.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- Market capitalization of $0.00B indicates a micro-cap or nano-cap valuation, reflecting the company's small size and limited operations.
- Negative profit margin of -232.3% highlights significant financial losses and operational inefficiencies.
- Gross margin of 36.6% suggests some ability to generate profit from sales, but this is overshadowed by high operating expenses.
- Negative free cash flow (FCF) indicates the company is not generating sufficient cash from its operations to cover its expenses and investments.
- Beta of 41.00 indicates extremely high volatility compared to the market, implying a high-risk investment.
Wettbewerber & Vergleichsunternehmen
Staerken
- Historical expertise in ozone technology.
- Potential intellectual property assets.
- Established brand name (historical).
- Potential for strategic partnerships.
Schwaechen
- Suspended operations since 2002.
- Lack of current revenue generation.
- Negative profit margin and free cash flow.
- Limited financial resources.
Katalysatoren
- Upcoming: Potential acquisition offer from a larger healthcare company.
- Upcoming: Securing new financing to resume operations.
- Ongoing: Research and development efforts to create new ozone-based products.
- Ongoing: Pursuit of strategic partnerships and licensing agreements.
Risiken
- Potential: Continued inability to secure financing and resume operations.
- Potential: Technological obsolescence of ozone technology.
- Ongoing: Intense competition from established players in the sterilization market.
- Ongoing: Limited liquidity and high volatility due to OTC listing.
- Ongoing: Risk of delisting from the OTC market.
Wachstumschancen
- Resumption of Operations: If Cyclo3pss were to secure new financing and resume operations, it could capitalize on the growing demand for advanced sterilization technologies in the food processing and healthcare industries. The market for food safety technologies is projected to reach billions of dollars, offering a substantial opportunity for growth if the company can regain its operational footing. Timeline: 2-5 years.
- Strategic Acquisition: Cyclo3pss's intellectual property and historical presence in the ozone technology sector could make it an attractive acquisition target for a larger company seeking to expand its portfolio. An acquisition could provide the necessary capital and resources to revitalize the company's operations and leverage its existing assets. Timeline: 1-3 years.
- Partnerships and Licensing: Cyclo3pss could explore partnerships and licensing agreements with other companies in the healthcare or food processing industries to generate revenue from its existing technologies. This approach would allow the company to leverage its intellectual property without the need for significant capital investment. Timeline: 1-2 years.
- Expansion into New Markets: The company could explore opportunities to expand its ozone technology into new markets, such as water treatment or air purification. These markets are experiencing growth due to increasing concerns about environmental sustainability and public health, offering potential avenues for diversification. Timeline: 3-5 years.
- Development of New Products: Cyclo3pss could invest in research and development to create new ozone-based products and solutions that address emerging needs in the sterilization and disinfection market. This could involve developing more efficient and cost-effective ozone generators or exploring new applications for ozone technology in healthcare settings. Timeline: 3-5 years.
Chancen
- Resumption of operations with new financing.
- Strategic acquisition by a larger company.
- Licensing of ozone technology to other businesses.
- Expansion into new markets and applications.
Risiken
- Competition from established players in the sterilization market.
- Technological obsolescence.
- Regulatory changes affecting ozone technology.
- Continued inability to secure financing.
Wettbewerbsvorteile
- Proprietary ozone technology (if patents are still valid).
- Established presence in the ozone technology market (historical).
- Potential for intellectual property licensing.
- First-mover advantage in specific niche markets (historical).
Ueber CYPS
Cyclo3pss Corporation, established in 1927 and based in Salt Lake City, Utah, is a company focused on the development, manufacture, and sale of ozone-based technologies. Initially, the company's core business revolved around ozone food processing products designed to enhance food safety and extend shelf life. Additionally, Cyclo3pss offered ozone washing and laundry sorting systems tailored for commercial and institutional laundries, aiming to improve efficiency and hygiene in these settings. The company also engaged in research and development efforts aimed at creating sterilization and disinfection technologies for consumer products. However, in July 2002, Cyclo3pss faced significant financial challenges, leading its Board of Directors to suspend all operations. This decision stemmed from the company's inability to secure necessary financing and attract willing investors to support its ongoing activities. Despite this operational suspension, Cyclo3pss remains a publicly listed entity, trading on the OTC market. The company's historical focus on ozone technology positions it within the broader landscape of sterilization and disinfection solutions, though its current operational status limits its active participation in the market.
Was das Unternehmen tut
- Licenses ozone food processing products.
- Manufactures ozone food processing products.
- Sells ozone food processing products.
- Installs ozone food processing products.
- Licenses ozone washing systems for commercial laundries.
- Manufactures ozone washing systems for commercial laundries.
- Sells ozone washing systems for commercial laundries.
- Engages in R&D of sterilization and disinfection technologies.
Geschaeftsmodell
- Licensing of ozone technology to other businesses.
- Direct sales of ozone-based products and systems.
- Installation and maintenance services for ozone systems.
- Research and development of new ozone-based applications.
Branchenkontext
Cyclo3pss Corporation operates within the diagnostics and research segment of the healthcare sector. This segment is characterized by innovation in sterilization and disinfection technologies. The market for ozone-based sterilization systems is competitive, with companies like CVHIF, EMGE, KLDO, NMRD, and NMXS offering alternative solutions. Given Cyclo3pss's operational suspension since 2002, it currently holds a marginal position in the industry, pending any potential resumption of operations or strategic repositioning.
Wichtige Kunden
- Food processing companies seeking to improve food safety.
- Commercial and institutional laundries aiming to enhance efficiency and hygiene.
- Potential partners in the healthcare and environmental sectors.
- Consumers seeking sterilization and disinfection solutions (future potential).
Finanzdaten
Chart & Info
Cyclo3pss Corporation (CYPS) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
Keine aktuellen Nachrichten fuer CYPS verfuegbar.
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer CYPS.
Kursziele
Wall-Street-Kurszielanalyse fuer CYPS.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von CYPS auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Wettbewerber & Vergleichsunternehmen
CYPS OTC-Marktinformationen
The OTC Other tier represents the lowest tier of the OTC market, encompassing stocks that may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited or no financial disclosure, making it difficult for investors to assess their financial health and operational performance. These securities are often considered highly speculative and carry significant risks due to the lack of transparency and regulatory oversight compared to NYSE or NASDAQ-listed companies.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited or no financial disclosure.
- High potential for fraud or manipulation.
- Lack of regulatory oversight.
- Extreme illiquidity.
- Going concern risk due to suspended operations.
- Verify the company's legal status and registration.
- Attempt to locate and review any available financial statements.
- Assess the validity and enforceability of any intellectual property.
- Investigate the background and reputation of the company's management.
- Understand the reasons for the company's operational suspension.
- Determine if there are any ongoing legal or regulatory issues.
- Evaluate the potential for a turnaround or strategic acquisition.
- Historical operating history prior to 2002.
- Existing intellectual property assets (if valid).
- Continued listing on the OTC market (though at the lowest tier).
- Company filings, if any, with regulatory authorities.
Was Anleger ueber Cyclo3pss Corporation (CYPS) wissen wollen
What are the key factors to evaluate for CYPS?
Cyclo3pss Corporation (CYPS) currently holds an AI score of 53/100, indicating moderate score. Key strength: Historical expertise in ozone technology.. Primary risk to monitor: Potential: Continued inability to secure financing and resume operations.. This is not financial advice.
How frequently does CYPS data refresh on this page?
CYPS prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven CYPS's recent stock price performance?
Recent price movement in Cyclo3pss Corporation (CYPS) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Historical expertise in ozone technology.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider CYPS overvalued or undervalued right now?
Determining whether Cyclo3pss Corporation (CYPS) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying CYPS?
Before investing in Cyclo3pss Corporation (CYPS), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding CYPS to a portfolio?
Potential reasons to consider Cyclo3pss Corporation (CYPS) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Historical expertise in ozone technology.. Additionally: Potential intellectual property assets.. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of CYPS?
Yes, most major brokerages offer fractional shares of Cyclo3pss Corporation (CYPS) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track CYPS's earnings and financial reports?
Cyclo3pss Corporation (CYPS) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for CYPS earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- Information is based on available data and may be incomplete due to the company's limited disclosure.
- The company's operational status and financial condition are highly uncertain.